<SUBMISSION>
<ACCESSION-NUMBER>0001019687-05-002852
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20051020
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20051020
<DATE-OF-FILING-DATE-CHANGE>20051020
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ACACIA RESEARCH CORP
<CIK>0000934549
<ASSIGNED-SIC>3670
<IRS-NUMBER>954405754
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26068
<FILM-NUMBER>051147422
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>500 NEWPORT CENTER DRIVE
<STREET2>7TH FLOOR
<CITY>NEWPORT BEACH
<STATE>CA
<ZIP>92660
<PHONE>9494808300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>500 NEWPORT CENTER DRIVE
<STREET2>#
<CITY>NEWPORT BEACH
<STATE>CA
<ZIP>92660
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acacia_8k-101905.txt
<TEXT>
<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                 --------------

                                    FORM 8-K

                                  -------------

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                OCTOBER 20, 2005
                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

                                  ------------

                           ACACIA RESEARCH CORPORATION
             (Exact name of Registrant as specified in its Charter)


         Delaware                     000-26068                 95-4405754
         --------                     ---------                 ----------
(State or Other Jurisdiction         (Commission               (I.R.S. Employer
       of Incorporation)             File Number)            Identification No.)


                            500 Newport Center Drive,
                         Newport Beach, California 92660
                    (Address of Principal Executive Offices)


                                 (949) 480-8300
               Registrant's telephone number, including area code


                                 Not Applicable
          (Former Name or Former Address, if Changed since Last Report)


<PAGE>


ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

         On October 20, 2005, Acacia Research Corporation issued a press release
announcing its earnings for the three months ended September 30, 2005. A copy of
that release is furnished as Exhibit 99.1 to this report.

         The information in this Current Report on Form 8-K is being furnished
and shall not be deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. The information in this Current Report shall not be incorporated
by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

         (c) Exhibits.

             99.1     Press Release dated October 20, 2005 of the
                      Registrant.


                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.


                               ACACIA RESEARCH CORPORATION


Date:  October 20, 2005        By:  /s/ Paul R. Ryan
                                    -------------------------------------------
                                    Name:  Paul R. Ryan
                                    Title: Chairman and Chief Executive Officer


                                       -2-


<PAGE>


                                  Exhibit Index


Exhibit Number          Description
--------------          -----------


     99.1               Press Release dated October 20, 2005, of the Registrant.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>acacia_8kex99-1.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
<PAGE>
EXHIBIT 99.1

[ACACIA LOGO]
                                                           CONTACTS: Rob Stewart
                                                              Investor Relations
FOR RELEASE                                                   Tel (949) 480-8300
-----------                                                   Fax (949) 480-8301
October 20, 2005


                      ACACIA RESEARCH REPORTS THIRD QUARTER
                                FINANCIAL RESULTS


         Newport Beach, Calif. - (BUSINESS WIRE) - October 20, 2005 - Acacia
Research Corporation (Nasdaq: ACTG; CBMX) today reported results for the three
months ended September 30, 2005. Acacia Research Corporation comprises two
operating groups, the Acacia Technologies group and the CombiMatrix group.

         "Acacia Technologies revenues for the third quarter of 2005 were
$6,783,000, an increase of 202% from the year ago period. We generated revenues
from 32 new licensing agreements covering 8 different licensing programs. New
licensees included Adidas, AMD, CVS Pharmacy, Gannett, LensCrafters,
Priceline.com, 7-Eleven, Samsung, Sony, Matsushita and the Tribune Company,"
commented Paul Ryan, Acacia Chairman & CEO.

         "Acacia generated revenues from 3 new licensing programs in the quarter
and has begun generating revenues from 11 of its 18 licensing programs. We
acquired control of 3 new patent portfolios that relate to digital inkjet
printing, high resolution optics, and hearing aid ECS technology and will
commence licensing programs for these technologies. We will continue to acquire
new patent portfolios as we move toward our goal of becoming the leader in
technology licensing," concluded Mr. Ryan.

         "The CombiMatrix group's revenues for the third quarter of 2005 were
$1,463,000, an increase of 94% from the prior year quarter. Revenues consisted
of $973,000 in government contract revenues and $490,000 in CustomArrayTM
product, equipment and service revenues," commented Dr. Amit Kumar, President
and CEO of CombiMatrix Corporation.

         "Including proceeds from recent offerings, we finished the quarter with
$24.7 million in cash and short-term investments, which will enable us to
continue to move forward with additional product introductions and to continue
investment in our CombiMatrix Molecular Diagnostics subsidiary," concluded Dr.
Kumar.

ACACIA RESEARCH CORPORATION CONSOLIDATED

FINANCIAL RESULTS

         Consolidated revenues for the third quarter of 2005 were $8,246,000
versus $2,993,000 in the comparable 2004 period. Third quarter 2005 revenues
recognized by the CombiMatrix group were $1,463,000, comprised of $973,000 in
government contract revenues and $490,000 in CustomArrayTM product, equipment
and service revenues.

         Third quarter 2005 revenues recognized by the Acacia Technologies group
were $6,783,000, comprised of $927,000 in recurring license fee revenues and
$5,856,000 in paid-up license fee revenues. Revenues in the comparable 2004
period were $2,240,000, comprised of $740,000 in recurring license fee revenues
and $1,500,000 in previously deferred, paid-up V-chip license fee revenues.


<PAGE>

Recurring license fee revenues are recognized from licensees that make recurring
quarterly or annual license fee payments under their respective license
agreements. Paid-up license fee revenues are recognized from licensees that make
paid-up license fee payments for past infringement and future use of our
patented technologies, in accordance with their respective license agreements.
Certain of our paid-up license agreements provide for potential additional
payments to the Acacia Technologies group based on future activities. All of the
paid-up license fee revenues recognized in the third quarter of 2005 relate to
patents acquired in the January 2005 acquisition of Global Patent Holdings, LLC
(the "GPH Acquisition"). Third quarter 2005 license fee revenues included fees
from the licensing of our Digital Media Transmission ("DMT(R)") technology,
audio/video enhancement and synchronization technology, computer memory cache
coherency technology, credit card fraud protection technology, interactive
television technology, interstitial internet advertising technology,
multi-dimensional bar code technology and network data storage technology.

         In the third quarter of 2005, the Acacia Technologies group recognized
contingent legal fee expenses totaling $1,834,000 and inventor royalty expenses
totaling $2,105,000, in connection with the recognition of related paid-up
license fee revenues.

         The third quarter 2005 consolidated net loss was $5,441,000 versus
$5,390,000 in the comparable 2004 period. The third quarter 2005 results
included net non-cash charges totaling $1,990,000, comprised primarily of patent
amortization charges of $1,607,000 and asset depreciation charges of $294,000.
Third quarter 2004 net non-cash charges were $824,000, primarily comprised of
patent amortization charges of $399,000, stock compensation charges of $147,000
and asset depreciation charges of $278,000. The increase in patent amortization
charges reflects the amortization of patent related intangibles acquired in
connection with the GPH Acquisition, totaling approximately $25.1 million, which
are being amortized over a weighted average economic useful life of
approximately 6 years. The third quarter 2005 results also included a non-cash
credit of $211,000 related to the expiration of all of the anti-dilution
provisions of the September 2002 settlement agreement between CombiMatrix
Corporation and Nanogen, Inc. and $225,000 of V-chip related inventor royalties
expense recognized as a result of the anticipated conclusion of all V-chip
related litigation activities in October of 2005.

         As a result of the conclusion of the Acacia Technologies group's V-chip
patent licensing program in August 2004, third quarter 2004 results include an
impairment charge of $1,616,000 associated with the write-off of goodwill
related to the V-chip, $1,500,000 of V-chip related deferred license fee
revenues and $668,000 of V-chip related deferred legal costs.

         Third quarter 2005 government contract costs totaled $920,000 versus
$647,000 in the comparable 2004 period. The change was due to increased costs
recognized in connection with the CombiMatrix group's commitments under its
biological threat detection contract with the Department of Defense. As of
September 30, 2005, the biological threat detection contract was approximately
85% complete. Third quarter 2005 internal research and development expenses were
$1,527,000 versus $1,140,000 in the comparable 2004 period. During the third
quarter of 2005 and 2004, the CombiMatrix group continued internal research and
development efforts to improve and expand the CombiMatrix group's technology and
product offerings. The increase in internal research and development expenses
was due primarily to the impact of the CombiMatrix group's wholly owned
subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began
operations during the second quarter of 2005.

         Marketing, general and administrative expenses for the third quarter of
2005 increased to $4,830,000 from $3,597,000 in the comparable 2004 period, due
primarily to the addition of licensing and business development personnel for
the Acacia Technologies group, an increase in the Acacia Technologies group's
consulting expenses related to a consulting agreement executed with the former
CEO of Global Patent Holdings, LLC, an increase in marketing and sales expenses
related to the commercial sale of CombiMatrix group's CustomArray(TM) products
and services and an increase in expenses related to CombiMatrix Molecular
Diagnostics, which began operations during the second quarter of 2005.

         Third quarter 2005 patent related legal expenses, incurred solely by
the Acacia Technologies group, were $1,076,000 versus $506,000 (excluding third
quarter 2004 deferred V-chip related legal expenses) in the comparable 2004
period. Third quarter 2005 patent related legal expenses included $183,000 in


<PAGE>

patent related prosecution and enforcement costs incurred by certain of the
companies acquired in the GPH Acquisition. Excluding the impact of the GPH
Acquisition, third quarter 2005 patent related legal expenses increased to
$893,000, due to an increase in ongoing DMT patent related litigation activity
in the third quarter of 2005. DMT related legal fees paid to outside attorneys
are incurred based on actual time and out-of-pocket expenses incurred by
external counsel and fluctuate from period to period based on patent enforcement
and prosecution activity in each period.

FINANCIAL CONDITION

         Total consolidated assets were $125,708,000 as of September 30, 2005
compared to $88,327,000 as of December 31, 2004. Cash and cash equivalents and
short-term investments on a consolidated basis totaled $65,709,000 as of
September 30, 2005 compared to $52,358,000 as of December 31, 2004.

         In July 2005, Acacia Research Corporation raised gross proceeds of
$3,151,000 through the sale of 1,400,444 shares of AR-CombiMatrix stock at a
price of $2.25 per share in a registered direct offering. Net proceeds raised of
approximately $3,114,000, which are net of related issuance costs, were
attributed to the CombiMatrix group.

         In September 2005, Acacia Research Corporation raised gross proceeds of
$10,537,000 through the sale of 6,385,907 shares of AR-CombiMatrix stock and
1,596,478 AR-CombiMatrix stock purchase warrants at a price of $1.65 per unit in
a registered direct offering. Each unit consisted of one share of AR-CombiMatrix
stock and one-quarter of a five-year AR-CombiMatrix stock purchase warrant. Each
full AR-CombiMatrix stock purchase warrant entitles the holder to purchase a
share of AR-CombiMatrix stock at a price of $2.40 per share and is exercisable
immediately upon issue. Net proceeds raised of approximately $9,707,000, which
are net of related issuance costs, were attributed to the CombiMatrix group. At
September 30, 2005, the fair value of the stock purchase warrants has been
classified as a long-term liability as a result of certain redemption provisions
associated with the underlying AR-CombiMatrix stock. Changes in the fair value
of the stock purchase warrant liability are reflected in the statement of
operations.

         Proceeds from these offerings are being used by the CombiMatrix group
for general working capital purposes. All of the shares of stock were offered
pursuant to an effective registration statement previously filed with the
Securities and Exchange Commission.

ACACIA TECHNOLOGIES GROUP
(A DIVISION OF ACACIA RESEARCH CORPORATION)

FINANCIAL RESULTS

         License fee revenues for the third quarter of 2005 were $6,783,000,
comprised of $927,000 in recurring license fee revenues and $5,856,000 in
paid-up license fee revenues. Revenues in the comparable 2004 period were
$2,240,000, comprised of $740,000 in recurring license fee revenues and
$1,500,000 in previously deferred, paid-up V-chip license fee revenues.
Recurring license fee revenues are recognized from licensees that make recurring
quarterly or annual license fee payments under their respective license
agreements. Paid-up license fee revenues are recognized from licensees that make
paid-up license fee payments for past infringement and future use of our
patented technologies, in accordance with their respective license agreements.
Certain of our paid-up license agreements provide for potential additional
payments based on future activities. All of the paid-up license fee revenues
recognized in the third quarter of 2005 relate to patents acquired in the
January 2005 GPH Acquisition. Third quarter 2005 license fee revenues included
fees from the licensing of our Digital Media Transmission ("DMT(R)") technology,
audio/video enhancement and synchronization technology, computer memory cache
coherency technology, credit card fraud protection technology, interactive
television technology, interstitial internet advertising technology,
multi-dimensional bar code technology and network data storage technology.


<PAGE>

         In the third quarter of 2005, the Acacia Technologies group recognized
contingent legal fee expenses totaling $1,834,000 and inventor royalty expenses
totaling $2,105,000, in connection with the recognition of related paid-up
license fee revenues.

         The third quarter 2005 division net loss was $1,558,000 versus
$1,842,000 in the comparable 2004 period. Included in the third quarter 2005
divisional results are non-cash charges totaling $1,474,000, primarily comprised
of patent amortization charges of $1,334,000 and stock compensation charges of
$123,000. Non-cash patent amortization charges were $125,000 in the comparable
2004 period. The increase in patent amortization charges reflects the scheduled
amortization of approximately $25.1 million in patent related intangibles
acquired in connection with the GPH Acquisition, which are being amortized over
a weighted average economic useful life of approximately 6 years. The third
quarter 2005 results also included $225,000 of V-chip related inventor royalties
expense recognized as a result of the anticipated conclusion of all V-chip
related litigation activities in October of 2005.

         As a result of the conclusion of the V-chip patent licensing program in
August 2004, third quarter 2004 results include an impairment charge of
$1,616,000 associated with the write-off of goodwill related to the V-chip,
$1,500,000 of V-chip related deferred license fee revenues and $668,000 of
V-chip related deferred legal costs.

         Third quarter 2005 marketing, general and administrative expenses
increased to $1,990,000 from $1,323,000 in the comparable 2004 period, due
primarily to the addition of licensing and business development personnel, an
increase in consulting expenses related to a consulting agreement executed with
the former CEO of Global Patent Holdings and an increase in general and
administrative expenses associated with ongoing operations. Third quarter 2005
general and administrative expenses included $205,000 in one-time, employee
relocation expenses.

         Third quarter 2005 patent related legal expenses were $1,076,000 versus
$506,000 (excluding third quarter 2004 deferred V-chip related legal expenses)
in the comparable 2004 period. Third quarter 2005 patent related legal expenses
included $183,000 in patent related prosecution and enforcement costs incurred
by certain of the companies acquired in the GPH Acquisition. Excluding the
impact of the GPH Acquisition, third quarter 2005 patent related legal expenses
increased to $893,000, due to an increase in ongoing DMT patent related
litigation activity in the third quarter of 2005. DMT related legal fees paid to
outside attorneys are incurred based on actual time and out-of-pocket expenses
incurred by external counsel and fluctuate from period to period based on patent
enforcement and prosecution activity in each period.

         It is anticipated that the majority of litigation expenses associated
with the recently acquired patent portfolios will be incurred on a contingency
basis where patent attorney fees are paid out of license fee revenues collected
based on a contractual percentage. In connection with the GPH Acquisition, we
expect that other legal expenses associated with the maintenance, licensing and
enforcement of our patented technologies, will increase in future periods as we
continue to roll out our licensing programs for our recently acquired patented
technologies.

FINANCIAL CONDITION

         Total assets for the Acacia Technologies group were $68,251,000 as of
September 30, 2005 compared to $33,058,000 as of December 31, 2004. Cash and
cash equivalents and short-term investments totaled $41,012,000 as of September
30, 2005 compared to $28,646,000 as of December 31, 2004.

COMBIMATRIX GROUP
(A DIVISION OF ACACIA RESEARCH CORPORATION)

FINANCIAL RESULTS


<PAGE>

         Revenues for the third quarter of 2005 were $1,463,000 versus $753,000
in the comparable 2004 period. Third quarter 2005 revenues were comprised of
$973,000 in government contract revenues and $490,000 in CustomArrayTM product,
equipment and service revenues.

         Government contract revenues relate to the CombiMatrix group's
development of biological threat detection technology under its $5.9 million
Department of Defense cost plus fixed fee contract, originally awarded in March
2004.
         The third quarter 2005 division net loss was $3,883,000 versus
$3,548,000 in the comparable 2004 period. The third quarter 2005 results
included non-cash patent amortization, asset depreciation and stock compensation
charges totaling $516,000 as compared to $686,000 in the comparable 2004 period.
The third quarter 2005 results included a non-cash credit of $211,000 related to
the expiration of all of the anti-dilution provisions of the September 2002
settlement agreement with Nanogen, Inc. as of September 30, 2005.

         Third quarter 2005 government contract costs totaled $920,000 versus
$647,000 in the comparable 2004 period. The change was due to increased costs
recognized in connection with the CombiMatrix group's commitments under its
biological threat detection contract with the Department of Defense. As of
September 30, 2005, the biological threat detection contract was approximately
85% complete. Third quarter 2005 internal research and development expenses were
$1,527,000 versus $1,140,000 in the comparable 2004 period. During the third
quarter of 2005 and 2004, the CombiMatrix group continued internal research and
development efforts to improve and expand the CombiMatrix group's technology and
product offerings. The increase in internal research and development expenses
was due primarily to the impact of the CombiMatrix group's wholly owned
subsidiary, CombiMatrix Molecular Diagnostics, which was formed and began
operations during the second quarter of 2005.

         Third quarter 2005 marketing, general and administrative expenses
increased to $2,840,000 versus $2,274,000 in the comparable 2004 period, due
primarily to an increase in marketing and sales expenses related to commercial
sales of the CombiMatrix group's CustomArray(TM) products and services and an
increase in expenses related to CombiMatrix Molecular Diagnostics, which began
operations during the second quarter of 2005.

FINANCIAL CONDITION

         Total assets for the CombiMatrix group were $57,457,000 as of September
30, 2005 compared to $55,388,000 as of December 31, 2004. Cash and cash
equivalents and short-term investments totaled $24,697,000 as of September 30,
2005 compared to $23,712,000 as of December 31, 2004.

         In July 2005, Acacia Research Corporation raised gross proceeds of
$3,151,000 through the sale of 1,400,444 shares of AR-CombiMatrix stock at a
price of $2.25 per share in a registered direct offering. Net proceeds raised of
approximately $3,114,000, which are net of related issuance costs, were
attributed to the CombiMatrix group.

         In September 2005, Acacia Research Corporation raised gross proceeds of
$10,537,000 through the sale of 6,385,907 shares of AR-CombiMatrix stock and
1,596,478 AR-CombiMatrix stock purchase warrants at a price of $1.65 per unit in
a registered direct offering. Each unit consisted of one share of AR-CombiMatrix
stock and one-quarter of a five-year AR-CombiMatrix stock purchase warrant. Each
full AR-CombiMatrix stock purchase warrant entitles the holder to purchase a
share of AR-CombiMatrix stock at a price of $2.40 per share and is exercisable
immediately upon issue. Net proceeds raised of approximately $9,707,000, which
are net of related issuance costs, were attributed to the CombiMatrix group. At
September 30, 2005, the fair value of the stock purchase warrants has been
classified as a long-term liability as a result of certain redemption provisions
associated with the underlying AR-CombiMatrix stock. Changes in the fair value
of the stock purchase warrant liability are reflected in the statement of
operations.

         Proceeds from these offerings are being used for general working
capital purposes.


<PAGE>

BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS
-------------------------------------------

Business highlights of the third quarter and recent developments include:

ACACIA TECHNOLOGIES GROUP:

         o        In July 2005, Financial Systems Innovation LLC, a wholly owned
                  subsidiary of the Acacia Technologies group, entered into a
                  non-exclusive license covering a patent that applies to credit
                  card fraud protection technology with LensCrafters, Inc.,
                  Sunglass Hut Trading Corporation, Pearle Vision, Inc., Cole
                  Vision Corporation, Watch World International, Inc., and
                  Things Remembered, Inc. Additional licenses were entered into
                  with 7-Eleven, Inc., Academy, Ltd., Michaels Stores, Inc.,
                  Coldwater Creek, Inc., The Dress Barn, Inc. and Whitehall
                  Jewellers, Inc. in August 2005 and with CVS Pharmacy, Inc. in
                  September 2005. The patented technology generally relates to a
                  computerized system for protecting retailers and consumers
                  engaged in credit card, check card, and debit transactions.

         o        In August 2005, Acacia Media Technologies Corporation, a
                  wholly owned subsidiary of the Acacia Technologies group,
                  entered into a non-exclusive license agreement for certain
                  uses of its Digital Media Transmission ("DMT(R)") technology
                  with Gannett Co, Inc., Internet Broadcasting Systems, Inc.,
                  Journal Communications, Inc., Landmark Communications, Inc.,
                  The E.W. Scripps Company, and Tribune Company. The Acacia
                  Technologies group's DMT(R) technology involves the
                  transmission and receipt of digital audio and/or audio video
                  content via a variety of means including the internet, cable,
                  satellite and local area networks. Elements of the DMT(R)
                  transmission process include a source material library,
                  identification encoding process, format conversion, sequence
                  encoding, compressed data storage and transmission. Elements
                  of the DMT(R) receiving process include a transceiver, format
                  conversion, storage, decompression and playback.

         o        In August 2005, VData, LLC, a wholly owned subsidiary that is
                  part of the Acacia Technologies group, entered into a
                  non-exclusive license with Adidas-Salomon AG, Adidas America,
                  Inc. and Paxar Corporation covering a portfolio of patents
                  that apply to certain multi-dimensional bar codes. The license
                  to Adidas resolves a patent infringement lawsuit against
                  Adidas and its related companies, which was pending in the
                  District Court for the District of Minnesota. An additional
                  license was entered into with Advanced Micro Devices, Inc.
                  ("AMD") which resolved a patent infringement lawsuit against
                  AMD, which was pending in the District Court for the District
                  of Minnesota.

                  The multi-dimensional bar code technology generally relates to
                  encoding and reading a data matrix consisting of an array of
                  data cells with a border. The data matrix can contain a
                  variety, amount, and depth of information that would not fit
                  on to an ordinary bar code. This patented technology can have
                  many applications in the manufacturing, distribution,
                  operations, accounting, and security industries such as
                  tracking the movement of products, collection of data,
                  improved production capabilities and anti-counterfeiting.

         o        In August 2005, InternetAd Systems, LLC, a wholly owned
                  subsidiary that is part of the Acacia Technologies group,
                  entered into a non-exclusive license with Priceline.com
                  Incorporated, covering a portfolio of patents that apply to
                  interstitial Internet advertising. The license to
                  Priceline.com resolves a patent infringement lawsuit against
                  Priceline.com which was pending in the District Court for the
                  Northern District of Texas, Dallas Division. The interstitial
                  Internet advertising technology generally relates to the
                  display of certain advertising, informational, and branding
                  messages that appear between or outside the web pages when the
                  user is conducting a search, by storing the message prior to
                  being displayed.

         o        In August 2005, IP Innovation, LLC, AV Technologies, LLC, and
                  New Medium Technologies, LLC, all wholly owned subsidiaries
                  that are part of the Acacia Technologies group, entered into a
                  non-exclusive license and settlement agreement with Sony
                  Corporation, covering patents that apply to Audio/Video
                  Enhancement and Synchronization, and Image Resolution
                  Enhancement technologies. The agreement with Sony resolves a
                  patent infringement lawsuit which was pending in the United
                  States District Court for the Northern District of Illinois.


<PAGE>

                  The Audio/Video Enhancement and Synchronization technologies
                  generally relate to the use of a noise reduction filtering
                  system for digital video compression, and for video and audio
                  signals received by digital radios and video displays. Other
                  aspects of the technologies apply to the synchronization of
                  audio/video signals. The Image Resolution Enhancement
                  Technology generally relates to the modification of a video or
                  printed display to improve the perceived image quality beyond
                  the basic pixel resolution of the display.

         o        In September 2005, KY Data Systems, LLC, a wholly owned
                  subsidiary that is part of the Acacia Technologies Group,
                  entered into non-exclusive licenses covering a portfolio of
                  patents that apply to interactive television with Matsushita
                  Electric Industrial Co., Ltd. and Samsung Electronics Co.,
                  Ltd. The patents cover receivers such as set-top boxes and
                  certain televisions used in digital satellite and digital
                  cable systems that permit television viewers to access
                  interactive television features supplied by their satellite
                  and cable providers as part of their digital programming
                  packages.

         o        In September 2005, Computer Cache Coherency Corporation, a
                  wholly owned subsidiary that is part of the Acacia
                  Technologies group, entered into a non-exclusive license with
                  AMD, covering a portfolio of patents that apply to certain
                  core logic computer chipsets. The license to AMD resolves a
                  patent infringement lawsuit against AMD, which was pending in
                  the District Court for the Northern District of California.
                  The Computer Memory Cache Coherency technology generally
                  relates to interface circuits used by intelligent peripheral
                  devices with cache memory to communicate with the main
                  computer memory. By synchronizing main computer memory and
                  main cache memory, the technology enables different memories
                  to communicate and synchronize with each other, allowing
                  peripheral devices to operate at faster speeds. This
                  technology can be used in desktop, notebook, and server
                  computer systems.

         o        During the third quarter of 2005, Acacia Patent Acquisition
                  Corporation, a wholly owned subsidiary that is part of the
                  Acacia Technologies group, continued its patent acquisition
                  activities as follows:

                  o        In July 2005, Acacia Patent Acquisition Corporation,
                           acquired several patents covering electromagnetic
                           compatibility shielding ("ECS") technology commonly
                           incorporated into hearing aids. The patented
                           technology shields hearing aids from electromagnetic
                           interference produced by portable electronic devices
                           such as cell phones, cordless phones, wireless
                           headphones and headsets, and WIFI and Bluetooth
                           enabled devices. The ECS technology can be
                           incorporated into many styles of hearing aids.

                  o        In August 2005, Acacia Patent Acquisition Corporation
                           acquired patents relating to a technology used to
                           improve print image quality for inkjet printers.
                           These patents cover a method of using digital
                           processing to create a row by row, column by column
                           matrix of color intensity values from an image, that
                           are stored into memory. These values are transformed
                           using a dither matrix, resulting in enhanced color
                           separation. Color inkjet printers are commonly used
                           to print photo quality pictures from digital cameras.

                  o        In September 2005, Acacia Patent Acquisition
                           Corporation acquired the rights to patents relating
                           to high resolution optics used by the military and in
                           commercial products. These patents generally relate
                           to refractive and diffractive systems and methods for
                           improving imaging capabilities in multi-element
                           optical systems by using fewer elements. The patented
                           systems and techniques have direct applications in
                           military imaging systems such as thermal weapon
                           sites, as well as commercial products like camera
                           lenses and optical printers.

                  o        In October 2005, Acacia Media Technologies
                           Corporation reached an accord with attorneys from the
                           university community on licensing terms for the use
                           of Acacia's DMT(R) technology. The revised license
                           offer includes an annual fixed fee royalty payment
                           that is based on the number of full-time equivalent


<PAGE>

                           (FTE) students, and exempts non-profit colleges and
                           universities with less than 1,000 students. The
                           revised terms will only be available to non-profit
                           U.S. colleges and universities that enter into the
                           license agreement on or before December 1, 2005.

COMBIMATRIX GROUP:

         o        In July 2005, the CombiMatrix group entered into a
                  non-exclusive agreement with J.K. International Inc. to
                  distribute CombiMatrix's CustomArray(TM) microarray products
                  in Japan. J.K. International's marketing and sales
                  organizations will market, sell, and service the CustomArrayTM
                  products.

         o        In July 2005, Acacia Research Corporation announced the
                  expansion of the management team at CombiMatrix Molecular
                  Diagnostics ("CMD"), a wholly owned subsidiary of CombiMatrix
                  Corporation and a cancer-based molecular diagnostics company
                  based in Irvine, California. CMD announced the appointment of
                  Dr. Mathew Moore, Director of Research and Development, Robert
                  Embree, Director of Laboratory Operations, and John Besser,
                  Chief Financial Officer.

         o        In August 2005, the CombiMatrix group announced that R. Scott
                  Greer joined CombiMatrix Corporation as an advisor. Mr. Greer
                  is managing director of Numenor Ventures, LLC, a firm he
                  formed to invest in and provide strategic advisory services to
                  innovative life science companies. He is a founder and remains
                  chairman of Abgenix, Inc., a public biopharmaceutical company.
                  Mr. Greer served as Chief Executive Officer of Abgenix from
                  June 1996 to April 2002. He is also a director of publicly
                  traded Sirna Therapeutics, Inc. and chairman of Acologix, a
                  private company. Previously, Mr. Greer was a director of
                  Ilumina, Inc. and CV Therapeutics, Inc., both publicly traded
                  companies.

         o        In August 2005, the CombiMatrix group announced the launch of
                  its first CustomArray(TM) DNA Synthesizer, enabling
                  researchers to build microarrays in their own facilities. For
                  the first time, pharmaceutical and academic core facilities
                  will have the ability to manufacture high quality, commercial
                  grade microarrays to their exact specifications with complete
                  control over customization. The platform consists of the DNA
                  CustomArrayTM Synthesizer instrument and freely programmable
                  microarrays or CustomArraysTM. Initially, the instrument has
                  been designed to fabricate the CustomArrayTM 12K (12,000
                  unique sites) array.

         o        In August 2005, the CombiMatrix group and the Biodesign
                  Institute at Arizona State University (the "Institute")
                  entered into a collaboration toward the development of a
                  peptide array synthesizer utilizing the CombiMatrix group's
                  proprietary virtual-flask technology. Under the terms of the
                  agreement, the Biodesign Institute's Center for BioOptical
                  Nanotechnology purchased CombiMatrix group equipment and will
                  be funding development of the synthesizer. The CombiMatrix
                  group is granting technology rights and contributing expertise
                  related to its technology, and the CombiMatrix group and the
                  Institute will share revenue from commercialization of peptide
                  array synthesizers, peptide array products, and intellectual
                  property that are developed.

         o        In August 2005, the CombiMatrix group announced that Dr. Eric
                  Whitman joined CombiMatrix's wholly owned subsidiary, CMD, as
                  a member of its Scientific Advisory Board and a Consultant in
                  the area of Melanoma Diagnosis and Management. Dr Whitman,
                  F.A.C.S., is the Administrative Director of Surgical Services
                  and the Director of the Melanoma Center at Mountainside
                  Hospital, in Montclair, New Jersey.

         o        In September 2005, the CombiMatrix group expanded its product
                  line to include the CustomArray(TM) 4X2K(TM). This product
                  contains four independent 2000-feature microarrays on a single
                  CustomArrayTM. As with all CustomArrayTM products, the 4X2K
                  offers complete array customization, user control of probe
                  design, and the ability to modify microarray design at any
                  time. It delivers high sensitivity, throughput, and ease of
                  use for gene discovery, pathway research, and molecular
                  characterization of disease. The 4X2K's introductory price is
                  $99 per 2000-feature microarray.


<PAGE>

         o        In September 2005, the CombiMatrix group entered into a global
                  distribution agreement with VWR International, Inc. ("VWR") to
                  distribute CustomArrays(TM) and CatalogArrays(TM) for the
                  CombiMatrix group. VWR's sales and marketing organization
                  presently serves over 250,000 customers with worldwide sales
                  of US$3.0 billion annually.

         o        In September 2005, the CombiMatrix Group received a one-year,
                  $338,000 contract from the U.S. Air Force for the development
                  and production of microarrays to detect pathogens that cause
                  upper respiratory infections and pathogens that infect wounds.
                  This contract is the result of a collaborative effort with the
                  Air Force Institute of Occupational Health ("AFIOH") that lead
                  to the development of a rapid assay and microarray that
                  identifies, among other things, all forms (serotypes) of
                  influenza A, SARS and bird flu, including the H5N1 strain. The
                  first array to be developed under the new contract will
                  identify a number of upper respiratory infections that can
                  cause potentially life threatening diseases (such as viral and
                  bacterial pneumonia) or lead to pandemic infections (such as
                  bird flu and SARS).

         A conference call is scheduled for today. The Acacia Technologies Group
presentation and Q&A will start at 1:15 p.m. Pacific Time (4:15 p.m. Eastern).
The CombiMatrix Group presentation and Q&A session will start at 2:00 p.m.
Pacific Time (5:00 p.m. Eastern).

         To listen to the presentation by phone, dial (800) 967-7187 for
domestic callers and (719) 457-2635 for international callers, both of whom will
need to provide the operator with the confirmation code 1072540. A replay of the
audio presentation will be available for 30 days at (888) 203-1112 for domestic
callers and (719) 457-0820 for international callers, both of whom will need to
enter the code 1072540 when prompted.

         The call is being webcast by CCBN and can be accessed at Acacia's
website at www.acaciaresearch.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies
group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented
technologies. Acacia controls 33 patent portfolios, which include over 120 U.S.
patents, and certain foreign counterparts, covering technologies used in a wide
variety of industries including audio/video enhancement & synchronization,
broadcast data retrieval, computer memory cache coherency, credit card fraud
protection, database management, data encryption & product activation, digital
media transmission (DMT(R)), digital video production, dynamic manufacturing
modeling, enhanced Internet navigation, high resolution optics, image resolution
enhancement, interactive data sharing, interactive television, hearing aid ECS,
interstitial Internet advertising, laptop docking station connectivity,
microprocessor enhancement, multi-dimensional bar codes, network data storage,
resource scheduling, rotational video imaging and spreadsheet automation.

The CombiMatrix group is developing a platform technology to rapidly produce
customizable arrays, which are semiconductor-based tools for use in identifying
and determining the roles of genes, gene mutations and proteins. The
CombiMatrix's group's technology has a wide range of potential applications in
the areas of genomics, proteomics, biosensors, drug discovery, drug development,
diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia
Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by
Acacia Research Corporation and are intended to reflect the performance of the
respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is
available at WWW.ACACIARESEARCH.COM.


SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995:

THIS NEWS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE
"SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995. THESE STATEMENTS ARE BASED UPON OUR CURRENT EXPECTATIONS AND SPEAK ONLY AS
OF THE DATE HEREOF. OUR ACTUAL RESULTS MAY DIFFER MATERIALLY AND ADVERSELY FROM
THOSE EXPRESSED IN ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF VARIOUS FACTORS
AND UNCERTAINTIES, INCLUDING THE RECENT ECONOMIC SLOWDOWN AFFECTING TECHNOLOGY
COMPANIES, OUR ABILITY TO SUCCESSFULLY DEVELOP PRODUCTS, RAPID TECHNOLOGICAL
CHANGE IN OUR MARKETS, CHANGES IN DEMAND FOR OUR FUTURE PRODUCTS, LEGISLATIVE,
REGULATORY AND COMPETITIVE DEVELOPMENTS AND GENERAL ECONOMIC CONDITIONS. OUR
ANNUAL REPORT ON FORM 10-K, RECENT AND FORTHCOMING QUARTERLY REPORTS ON FORM
10-Q, RECENT CURRENT REPORTS ON FORMS 8-K AND 8-K/A, AND OTHER SEC FILINGS
DISCUSS SOME OF THE IMPORTANT RISK FACTORS THAT MAY AFFECT OUR BUSINESS, RESULTS
OF OPERATIONS AND FINANCIAL CONDITION. WE UNDERTAKE NO OBLIGATION TO REVISE OR
UPDATE PUBLICLY ANY FORWARD-LOOKING STATEMENTS FOR ANY REASON.


<PAGE>

                           ACACIA RESEARCH CORPORATION
                          SUMMARY FINANCIAL INFORMATION
             (IN THOUSANDS, EXCEPT SHARE AND PER SHARE INFORMATION)
                                   (UNAUDITED)

CONSOLIDATED BALANCE SHEET INFORMATION

                                                   SEPTEMBER 30,    DECEMBER 31,
                                                       2005             2004
                                                     --------         --------

Total Assets                                         $125,708         $ 88,327
                                                     ========         ========
Total Liabilities                                    $ 15,738         $ 11,913
                                                     ========         ========
Minority Interests                                   $    486         $    778
                                                     ========         ========
Total Stockholders' Equity                           $109,484         $ 75,636
                                                     ========         ========

CONSOLIDATED STATEMENTS OF OPERATIONS

<TABLE>
<S> <C>


                                                                   FOR THE THREE MONTHS ENDED           FOR THE NINE MONTHS ENDED
                                                                -------------------------------     -------------------------------
                                                                SEPTEMBER 30,     SEPTEMBER 30,     SEPTEMBER 30,     SEPTEMBER 30,
                                                                    2005              2004              2005              2004
                                                                -------------     -------------     -------------     -------------
Revenues:
  Research and development contract ........................    $          --     $          --     $          --     $      17,302
  License fees .............................................            6,783             2,240            11,328             3,505
  Government contract ......................................              973               685             2,985             1,603
  Products and services ....................................              490                68             1,404               214
                                                                -------------     -------------     -------------     -------------

    Total revenues .........................................            8,246             2,993            15,717            22,624
                                                                -------------     -------------     -------------     -------------

Operating expenses:
  Cost of government contract revenues .....................              920               647             2,820             1,505
  Cost of product sales ....................................              282                41               635                81
  Research and development expenses ........................            1,527             1,140             4,082             3,932
  Non-cash stock compensation amortization -
    research and development ...............................               --               (10)               --                91
  Marketing, general and administrative expenses ...........            4,830             3,597            12,980            10,269
  Legal expenses - patents .................................            1,076             1,174             2,173             2,352
  Contingent legal fees and inventor royalties
    expense - patents ......................................            3,939                --             5,706                --
  Inventor royalties - V-chip ..............................              225                --               225                --
  Non-cash stock compensation amortization - marketing,
    general and administrative .............................               88               157               (23)              634
  Goodwill impairment charge ...............................               --             1,616                --             1,616
  Amortization of patents ..................................            1,607               399             4,407             1,197
  Legal settlement charges (credits) .......................             (211)              (90)             (406)              776
  Warrant charges (credits) ................................             (163)               --              (163)               --
                                                                -------------     -------------     -------------     -------------

    Total operating expenses ...............................           14,120             8,671            32,436            22,453
                                                                -------------     -------------     -------------     -------------

    Operating income (loss) ................................           (5,874)           (5,678)          (16,719)              171
                                                                -------------     -------------     -------------     -------------

Other income (expense):
  Interest income ..........................................              434               218             1,089               568
  Other expense ............................................             (100)               --              (201)               --
                                                                -------------     -------------     -------------     -------------

    Total other income .....................................              334               218               888               568
                                                                -------------     -------------     -------------     -------------

Income (loss) from continuing operations before
   income taxes and minority interests .....................           (5,540)           (5,460)          (15,831)              739

Benefit for income taxes ...................................               98                70               232               206
                                                                -------------     -------------     -------------     -------------

Income (loss) from continuing operations before
   minority interests ......................................           (5,442)           (5,390)          (15,599)              945

Minority interests .........................................                1                --                 1                 3
                                                                -------------     -------------     -------------     -------------

Income (loss) from continuing operations ...................           (5,441)           (5,390)          (15,598)              948
                                                                -------------     -------------     -------------     -------------

Discontinued operations:
   Estimated loss on disposal of discontinued operations ...               --                --              (210)             (104)
                                                                -------------     -------------     -------------     -------------

Net income (loss) ..........................................    $      (5,441)    $      (5,390)    $     (15,808)    $         844
                                                                =============     =============     =============     =============

Earnings (loss) per common share:
Attributable to the Acacia Technologies group:
  Net loss .................................................    $      (1,558)    $      (1,842)    $      (5,192)    $      (3,984)
    Basic and diluted loss per share .......................            (0.06)            (0.09)            (0.20)            (0.20)

Attributable to the CombiMatrix group:
Basic
  Net income (loss) ........................................    $      (3,883)    $      (3,548)    $     (10,616)    $       4,828
    Basic earnings (loss) per share ........................            (0.12)            (0.11)            (0.33)             0.16
Diluted
  Net income (loss) ........................................    $      (3,883)    $      (3,548)    $     (10,616)    $       4,828
    Diluted earnings (loss) per share ......................            (0.12)            (0.11)            (0.33)             0.16

Weighted average shares:
  Acacia Research - Acacia Technologies stock:
    Basic and diluted ......................................       27,302,693        19,793,487        26,387,562        19,777,820
                                                                =============     =============     =============     =============
Acacia Research - CombiMatrix stock:
    Basic ..................................................       33,239,726        30,962,190        31,887,872        29,570,562
                                                                =============     =============     =============     =============
    Diluted ................................................       33,239,726        30,962,190        31,887,872        30,789,229
                                                                =============     =============     =============     =============


<PAGE>

                            ACACIA TECHNOLOGIES GROUP
                   (A DIVISION OF ACACIA RESEARCH CORPORATION)
                          SUMMARY FINANCIAL INFORMATION
                                 (IN THOUSANDS)
                                   (UNAUDITED)

GROUP BALANCE SHEET INFORMATION

                                                   SEPTEMBER 30,    DECEMBER 31,
                                                       2005            2004
                                                     -------          -------

Total Assets                                         $68,251          $33,058
                                                     =======          =======
Total Liabilities                                    $ 5,194          $ 3,472
                                                     =======          =======
Minority Interests                                   $   486          $   778
                                                     =======          =======
Total Stockholders' Equity                           $62,571          $28,808
                                                     =======          =======


GROUP STATEMENTS OF OPERATIONS


                                                                     FOR THE THREE MONTHS ENDED         FOR THE NINE MONTHS ENDED
                                                                   ------------------------------    ------------------------------
                                                                   SEPTEMBER 30,    SEPTEMBER 30,    SEPTEMBER 30,    SEPTEMBER 30,
                                                                       2005             2004             2005             2004
                                                                   -------------    -------------    -------------    -------------
Revenues:
  License fees ..................................................  $       6,783    $       2,240    $      11,328    $       3,505
                                                                   -------------    -------------    -------------    -------------

    Total revenues ..............................................          6,783            2,240           11,328            3,505
                                                                   -------------    -------------    -------------    -------------

Operating expenses:
  Marketing, general and administrative expenses ................          1,990            1,323            5,359            3,489
  Legal expenses - patents ......................................          1,076            1,174            2,173            2,352
  Non-cash stock compensation amortization ......................            123               --              123               --
  Goodwill impairment charge ....................................             --            1,616               --            1,616
  Contingent legal fees and inventor royalties
    expense - patents ...........................................          3,939               --            5,706               --
  Inventor royalties - V-chip ...................................            225               --              225               --
  Amortization of patents .......................................          1,334              125            3,586              375
                                                                   -------------    -------------    -------------    -------------

    Total operating expenses ....................................          8,687            4,238           17,172            7,832
                                                                   -------------    -------------    -------------    -------------

    Operating loss ..............................................         (1,904)          (1,998)          (5,844)          (4,327)
                                                                   -------------    -------------    -------------    -------------

Other income:
  Interest income ...............................................            312              120              761              340
  Other income ..................................................             --               --                1               --
                                                                   -------------    -------------    -------------    -------------

    Total other income ..........................................            312              120              762              340
                                                                   -------------    -------------    -------------    -------------

Loss from continuing operations before
  income taxes and minority interests ...........................         (1,592)          (1,878)          (5,082)          (3,987)

Benefit for income taxes ........................................             33               36               99              104
                                                                   -------------    -------------    -------------    -------------

Loss from continuing operations before
  minority interests ............................................         (1,559)          (1,842)          (4,983)          (3,883)

Minority interests ..............................................              1               --                1                3
                                                                   -------------    -------------    -------------    -------------

Loss from continuing operations .................................         (1,558)          (1,842)          (4,982)          (3,880)

Discontinued operations:

  Estimated loss on disposal of discontinued operations .........             --               --             (210)            (104)
                                                                   -------------    -------------    -------------    -------------

Division net loss ...............................................  $      (1,558)   $      (1,842)   $      (5,192)   $      (3,984)
                                                                   =============    =============    =============    =============


<PAGE>

                                COMBIMATRIX GROUP
                   (A DIVISION OF ACACIA RESEARCH CORPORATION)
                          SUMMARY FINANCIAL INFORMATION
                                 (IN THOUSANDS)
                                   (UNAUDITED)

GROUP BALANCE SHEET INFORMATION

                                               SEPTEMBER 30,    DECEMBER 31,
                                                    2005            2004
                                                  -------         -------

Total Assets                                      $57,457         $55,388
                                                  =======         =======
Total Liabilities                                 $10,544         $ 8,560
                                                  =======         =======
Minority Interests                                $    --         $    --
                                                  =======         =======
Total Stockholders' Equity                        $46,913         $46,828
                                                  =======         =======


GROUP STATEMENTS OF OPERATIONS


                                                              FOR THE THREE MONTHS ENDED          FOR THE NINE MONTHS ENDED
                                                            ------------------------------      ------------------------------
                                                            SEPTEMBER 30,     SEPTEMBER 30,     SEPTEMBER 30,     SEPTEMBER 30,
                                                                2005              2004              2005              2004
                                                            ------------      ------------      ------------      ------------
Revenues:
  Research and development contract ...................     $         --      $         --      $         --      $     17,302
  Government contract .................................              973               685             2,985             1,603
  Products and services ...............................              490                68             1,404               214
                                                            ------------      ------------      ------------      ------------

    Total revenues ....................................            1,463               753             4,389            19,119
                                                            ------------      ------------      ------------      ------------

Operating expenses:
  Cost of government contract revenues ................              920               647             2,820             1,505
  Cost of product sales ...............................              282                41               635                81
  Research and development expenses ...................            1,527             1,140             4,082             3,932
  Non-cash stock compensation amortization -
    research and development ..........................               --               (10)               --                91
  Marketing, general and administrative expenses ......            2,840             2,274             7,621             6,780
  Non-cash stock compensation amortization -
    marketing, general and administrative .............              (35)              157              (146)              634
  Amortization of patents .............................              273               274               821               822
  Legal settlement charges (credits) ..................             (211)              (90)             (406)              776
  Warrant charges (credits) ...........................             (163)               --              (163)               --
                                                            ------------      ------------      ------------      ------------

    Total operating expenses ..........................            5,433             4,433            15,264            14,621
                                                            ------------      ------------      ------------      ------------

    Operating income (loss) ...........................           (3,970)           (3,680)          (10,875)            4,498
                                                            ------------      ------------      ------------      ------------

Other income (expense):
  Interest income .....................................              122                98               328               228
  Other expense .......................................             (100)               --              (202)               --
                                                            ------------      ------------      ------------      ------------

    Total other income ................................               22                98               126               228
                                                            ------------      ------------      ------------      ------------

Income (loss) from operations before income taxes .....           (3,948)           (3,582)          (10,749)            4,726

Benefit for income taxes ..............................               65                34               133               102
                                                            ------------      ------------      ------------      ------------

Division net income (loss) ............................     $     (3,883)     $     (3,548)     $    (10,616)     $      4,828
                                                            ============      ============      ============      ============

</TABLE>
</TEXT>
</DOCUMENT>
</SUBMISSION>
